Aethlon Medical (AEMD) announced that U.S. Patent No. 12,409,260 directed to treatment of Long COVID will issue on September 9, 2025, and Unitary European Patent 4136453 directed to the treatment of COVID-19-associated coagulopathy, or CAC, issued July 9. The 260 Patent is intended to protect the use of the Hemopurifier in the U.S. to treat patients that have a reduced COVID-19 viral load but exhibit Long COVID symptoms for more than 12 weeks post infection. The 260 Patent additionally protects the treatment of patients experiencing Long COVID symptoms by the removal of circulating COVID-19 spike protein. The 453 Patent is intended to protect the use of the Hemopurifier for the treatment of patients that lack circulating COVID-19 viral particles but exhibit COVID-19-associated CAC. The 260 Patent was granted an additional 385 days of patent term due to patent term adjustment and will expire in 2042. The 453 Patent will expire in 2041.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AEMD:
- Aethlon’s Earnings Call Highlights Progress and Strategic Focus
- Why Is Aethlon Medical Stock (AEMD) Up 60% Today?
- Aethlon Medical Highlights Hemopurifier® Potential in Presentation
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Aethlon Medical files to sell common stock, warrants, no amount given